Zacks Investment Research downgraded shares of Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) from a hold rating to a sell rating in a report published on Wednesday morning.
According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “
BHVN has been the topic of several other research reports. Morgan Stanley initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a report on Wednesday, May 31st. They issued an overweight rating on the stock. William Blair initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set an outperform rating and a $46.00 price objective on the stock. Barclays PLC initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set an overweight rating and a $30.00 price objective on the stock. Piper Jaffray Companies initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set an overweight rating and a $21.00 price objective on the stock. Finally, Needham & Company LLC initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set a buy rating and a $30.00 price objective on the stock. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company has an average rating of Buy and a consensus target price of $31.75.
Shares of Biohaven Pharmaceutical Holding Co (BHVN) opened at 28.52 on Wednesday. The firm’s market cap is $1.02 billion. Biohaven Pharmaceutical Holding Co has a one year low of $17.00 and a one year high of $28.79. The stock’s 50 day moving average is $25.10 and its 200-day moving average is $23.97.
WARNING: “Zacks Investment Research Downgrades Biohaven Pharmaceutical Holding Co Ltd (BHVN) to Sell” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://stocknewstimes.com/2017/08/19/zacks-investment-research-downgrades-biohaven-pharmaceutical-holding-co-ltd-bhvn-to-sell.html.
About Biohaven Pharmaceutical Holding Co
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Get a free copy of the Zacks research report on Biohaven Pharmaceutical Holding Co (BHVN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.
